1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Medartis Holding AG

Medartis Holding AG

MDRSF
Medartis Holding AGUS flagOther OTC
115.00
USD
- -
- -
1.43BMarket Cap
Medartis Holding AG
MDRSF
(Other OTC)

Recent

price

115.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
7.01
7.88
8.95
11.42
11.08
10.85
13.55
15.45
17.33
18.16
21.69
Revenue per Share
- -
0.62
0.28
0.07
0.4
0.18
-0.08
0.58
-0.49
0.05
0.29
0.67
Basic EPS, GAAP
- -
0.07
0.29
0.19
-0.76
-0.89
-0.04
0.9
-1.92
0.1
1.69
0.75
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-4.26
-3.77
-3.81
-3.52
-3.41
-3.52
-2.69
-1.75
-2.32
-1.34
-0.44
Book Value per Share
- -
-4.11
1.34
0.74
19.67
17.3
17.13
17.97
14.18
15.56
17.59
2.78
Tangible Book Value per Share
- -
12
12
12
11
12
12
12
12
12
12
12
Basic Weighted Avg Shares
- -
82
93
105
121
130
128
160
183
212
225
269
Sales/Revenue/Turnover
- -
14.76
7.82
9.15
4.99
5.65
2.43
6.89
-1.02
3.92
3.21
0.72
Operating Margin (%)
- -
6
7
7
8
13
16
16
18
23
22
25
Depreciation Expense
- -
7
3
1
4
2
-1
7
-6
1
4
8
Net Income, GAAP
- -
4.99
37.34
89.23
- -
35.33
- -
17.51
- -
65.44
- -
27
Effective Tax Rate (%)
- -
8.83
3.58
0.82
3.46
1.65
-0.74
4.28
-3.16
0.29
1.57
3.1
Profit Margin (%)
20
27
32
31
163
151
135
141
98
95
215
107
Working Capital
67
76
62
62
2
23
23
19
22
21
113
132
LT Debt
-54
-47
17
17
218
216
213
224
238
255
270
276
Total Equity
- -
41.24
7.58
1.14
- -
2.04
- -
3.7
- -
1.05
- -
0.34
Return on Invested Capital (%)
- -
32.74
15.65
3.76
- -
-11.41
- -
-67.83
- -
33.72
- -
10
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
106.82%
5.32%
2.31%
Free Cash Flow
-147.45%
-244.91%
-55.47%
Net Income, GAAP
-44.96%
-102.67%
136.65%
Sales/Revenue/Turnover
12.82%
16.27%
19.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
212
2024
- -
- -
- -
- -
225
2025
- -
- -
- -
- -
269

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.05
2024
- -
- -
- -
- -
0.29
2025
- -
- -
- -
- -
0.67

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Drägerwerk AG & Co. KGaA (0MT8.L)
Codex DNA, Inc. (DNAY)
InspireMD, Inc. (NSPR)
Manhattan Scientifics, Inc. (MHTX)
Iconovo AB (publ) (ICO.ST)
ViewRay, Inc. (VRAY)
Business
Medartis Holding AG, a Switzerland-based holding company of the Medartis Group founded in 1997 and headquartered in Basel, develops, manufactures and markets medical devices and implants for the surgical fixation of bone fractures and joint replacement in upper and lower extremities as well as the craniomaxillofacial region; its core product portfolio encompasses titanium screws and plates such as APTUS, Modus and SpeedTip systems, cannulated compression screws (CCS), intramedullary nails, Hand New Generation and Scaphoid plating solutions, Dorsal Olecranon plates, CMX personalized patient-specific implants and services, alongside the KeriMedical TOUCH prosthesis for thumb osteoarthritis; the company serves orthopedic, trauma and cranio-maxillofacial surgeons through subsidiaries in 13 locations including Warsaw (Indiana, USA), Umkirch (Germany) and direct sales in over 50 countries spanning EMEA, US, APAC and LATAM regions. Recent strategic developments include the full acquisition of KeriMedical in 2025 for CHF 99 million following FDA approval of its TOUCH prosthesis, enhancing joint replacement capabilities and surgeon networks in hand and wrist segments with added production in Archamps and Besançon, France; a majority 51% stake acquisition in NeoOrtho in Curitiba, Brazil announced with 2024 results for entry into the value segment of Latin American orthopedics with plans for full ownership by 2028/29 and a new modular facility by end-2025; US expansion via the Avenger Radial Head System from In2Bones Global in early 2025 to bolster elbow reconstruction; transition to direct sales in Japan expanding upper and lower extremities with sterile options and IBRA educational programs; in-sourcing of sterile packaging at Basel validated in 2024 targeting 70% internal production by spring 2025; and a CHF 115.8 million convertible bond issuance in April 2024 maturing 2031 to fund acquisitions alongside leadership changes including new CEO Matthias Schupp and US President David Thoni.

Company News

APIChatGPT

  • seekingalpha.com

    Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products Transcript

  • defenseworld.net

    Medartis Holding AG (OTCMKTS:MDRSF) Short Interest Down 12.8% in February